Drug intelligence / Profile preview

UA165HN1

Development stage: Preclinical
Lead developer: Aucta Pharmaceuticals
Modality: Small Molecules

Overview

UA165HN1 is a pipeline candidate currently under development by Aucta Pharmaceuticals, a specialty pharmaceutical company that utilizes the 505(b)(2) and ANDA regulatory pathways. The drug is positioned within the company's neurology portfolio, though the specific clinical indication and molecular target remain undisclosed. As Aucta Pharmaceuticals focuses on the reformulation and repositioning of existing therapeutic agents, UA165HN1 is likely an optimized version of a known neurological drug, potentially featuring an improved delivery system, modified release profile, or a new dosage form intended to enhance patient compliance or therapeutic efficacy.

Beyond the preview

Go deeper on UA165HN1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UA165HN1.

Explore the full profile